Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Anus Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pleural Neoplasms 1Peritoneal Neoplasms 1Mediastinal Neoplasms 1HIV Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anal Canal Carcinoma 1

Interventions

Gemcitabine 15Cisplatin 9Paclitaxel 6Nivolumab 5Fluorouracil 4Carboplatin 4atezolizumab 3Sunitinib 3Specimen Handling 3Radiotherapy 3Doxorubicin 3pegfilgrastim 2eribulin 2cabozantinib 2avelumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Ifosfamide 2Docetaxel 2CTLA-4 Antigen 2Biopsy 2vinflunine 1vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1rubitecan 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urethral Neoplasms × Mitozytrex × Clear all
NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Mayo Clinic

Phase 2 Completed
2 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡